WO2003011224A3 - Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same - Google Patents
Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same Download PDFInfo
- Publication number
- WO2003011224A3 WO2003011224A3 PCT/US2002/024262 US0224262W WO03011224A3 WO 2003011224 A3 WO2003011224 A3 WO 2003011224A3 US 0224262 W US0224262 W US 0224262W WO 03011224 A3 WO03011224 A3 WO 03011224A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lapachone
- beta
- pharmaceutically acceptable
- carrier molecule
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003516456A JP2005507861A (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions comprising β-lapachone, or derivatives or analogs thereof, and methods of use thereof |
CA002455567A CA2455567A1 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US10/343,091 US7074824B2 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
NZ531335A NZ531335A (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
KR1020047001569A KR100734341B1 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
AU2002313713A AU2002313713B2 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
IL16010802A IL160108A0 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same |
EP02753423A EP1420777A4 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
BR0211613-8A BR0211613A (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and processes for their use |
EA200400242A EA007075B1 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
MXPA04000994A MXPA04000994A (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same. |
US11/140,838 US20050245599A1 (en) | 2001-07-31 | 2005-05-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
IL192937A IL192937A0 (en) | 2001-07-31 | 2008-07-21 | Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30893501P | 2001-07-31 | 2001-07-31 | |
US60/308,935 | 2001-07-31 | ||
US09/975,776 US6962944B2 (en) | 2001-07-31 | 2001-10-10 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US09/975,776 | 2001-10-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/975,776 Continuation-In-Part US6962944B2 (en) | 2001-07-31 | 2001-10-10 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/140,838 Continuation US20050245599A1 (en) | 2001-07-31 | 2005-05-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011224A2 WO2003011224A2 (en) | 2003-02-13 |
WO2003011224A3 true WO2003011224A3 (en) | 2003-05-08 |
Family
ID=26976533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024262 WO2003011224A2 (en) | 2001-07-31 | 2002-07-31 | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
Country Status (13)
Country | Link |
---|---|
US (1) | US6962944B2 (en) |
EP (1) | EP1420777A4 (en) |
JP (1) | JP2005507861A (en) |
KR (1) | KR100734341B1 (en) |
CN (1) | CN1561209A (en) |
AU (1) | AU2002313713B2 (en) |
BR (1) | BR0211613A (en) |
CA (1) | CA2455567A1 (en) |
EA (1) | EA007075B1 (en) |
IL (2) | IL160108A0 (en) |
MX (1) | MXPA04000994A (en) |
NZ (1) | NZ531335A (en) |
WO (1) | WO2003011224A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308180B2 (en) | 2005-08-31 | 2016-04-12 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
US20050197405A1 (en) * | 2000-11-07 | 2005-09-08 | Li Chiang J. | Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent |
US20040241094A1 (en) * | 2001-09-13 | 2004-12-02 | Hesson Chung | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
WO2003090710A1 (en) * | 2002-04-23 | 2003-11-06 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
JP2005538981A (en) * | 2002-07-17 | 2005-12-22 | アーキュル, インコーポレイテッド | Activation checkpoint therapy and methods of use thereof |
US7361691B2 (en) | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
JP2007512378A (en) * | 2003-11-26 | 2007-05-17 | アークル インコーポレイテッド | Use of β-lapachone to protect against radiation damage |
CA2555950A1 (en) | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for the treatment of pancreatic cancer |
US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
WO2005082355A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treatment of colon cancer |
EP1729760A2 (en) * | 2004-02-20 | 2006-12-13 | Arqule, Inc. | Use of beta-lapachone for the treatment of lung cancer |
US20050192247A1 (en) * | 2004-02-23 | 2005-09-01 | Li Chiang J. | Method of treating cancers |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
US8614228B2 (en) * | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
WO2006020722A2 (en) * | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting |
ITMI20041763A1 (en) * | 2004-09-16 | 2004-12-16 | Altergon Sa | NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE |
TW200824692A (en) * | 2006-08-21 | 2008-06-16 | Arqule Inc | Novel lapachone compounds and methods of use thereof |
TWI401081B (en) | 2007-04-30 | 2013-07-11 | Arqule Inc | Hydroxy sulfonate of quinone compounds and their uses |
MX2009013815A (en) | 2007-06-22 | 2010-03-01 | Arqule Inc | Quinazolinone compounds and methods of use thereof. |
CA2735167A1 (en) | 2007-08-27 | 2009-03-05 | Boston Biomedical, Inc. | Composition of asymmetric rna duplex as microrna mimetic or inhibitor |
EP2217580B1 (en) | 2007-10-12 | 2011-12-21 | ArQule, Inc. | Substituted tetrazole compounds and uses thereof |
US8067459B2 (en) * | 2007-10-16 | 2011-11-29 | Arqule, Inc. | Lapachone compounds and methods of use thereof |
KR101405823B1 (en) | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | Pharmaceutical Composition for the Treatment and Prevention of glaucoma |
KR20090071829A (en) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | Pharmaceutical composition for treatment and prevention of kidney diseases |
KR20090073381A (en) * | 2007-12-31 | 2009-07-03 | 주식회사 머젠스 | Pharmaceutical composition for the treatment and prevention of cardiac disease |
KR101528265B1 (en) * | 2010-04-16 | 2015-06-11 | 코웨이 주식회사 | Cosmetic Composition for Reducing Skin Wrinkle Comprising beta-Lapachone |
US20130261142A1 (en) * | 2010-12-15 | 2013-10-03 | Hung-Cheng Lai | Compounds used for treating cancer and the use thereof |
KR101583755B1 (en) | 2012-10-29 | 2016-01-19 | 코웨이 주식회사 | Composition for preventing and treating of nervous system disease containing beta-lapachone as an effective ingredient |
RU2530886C1 (en) * | 2013-06-24 | 2014-10-20 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Water-soluble complex of beta-cyclodextrine-histochrome initiation, possessing prolonged antioxidant action |
WO2019143192A1 (en) * | 2018-01-18 | 2019-07-25 | (주)나디안바이오 | Composition comprising dunnione as effective ingredient for prevention or alleviation of hair loss |
CN112076157B (en) * | 2019-06-14 | 2022-04-26 | 首都医科大学 | Lapalol nanoliposome preparation and preparation method and application thereof |
WO2022010322A1 (en) * | 2020-07-10 | 2022-01-13 | (주)나디안바이오 | Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients |
KR20240014533A (en) | 2021-05-29 | 2024-02-01 | 1글로브 헬스 인스티튜트 엘엘씨 | Short duplex DNA and its uses as a novel gene silencing technology |
EP4347829A1 (en) | 2021-05-29 | 2024-04-10 | 1Globe Health Institute LLC | Asymmetric short duplex dna as a novel gene silencing technology and use thereof |
WO2023113479A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969163A (en) * | 1996-02-20 | 1999-10-19 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth |
WO2000061142A1 (en) * | 1999-04-14 | 2000-10-19 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2827452A (en) | 1955-05-31 | 1958-03-18 | Univ Minnesota | Stabilization of materials |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
HU184066B (en) | 1979-12-28 | 1984-06-28 | Chinoin Gyogyszer Es Vegyeszet | Plant growth regulating substance and process for preparing such compound |
HU181703B (en) | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
US4371673A (en) | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
NZ199543A (en) | 1981-01-23 | 1985-04-30 | Wellcome Found | Inclusion complexes of cyclodextrins and cardiac clycosides;pharmaceutical formulations |
JPS57126802A (en) | 1981-01-30 | 1982-08-06 | Mitsubishi Petrochem Co Ltd | Benzophenone-3,3'-disulfonate-capped compound of beta-cyclodextrin |
JPS57200361A (en) | 1981-06-03 | 1982-12-08 | Sumitomo Chem Co Ltd | "indomethacin(r)" pharmaceutical with low irritant action |
US4383992A (en) | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
JPS58144376A (en) | 1982-02-23 | 1983-08-27 | Sumitomo Chem Co Ltd | Clathrate compound of benzodiazepine derivative in cyclodextrin |
HU190818B (en) | 1982-11-09 | 1986-11-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
HU190584B (en) | 1983-03-11 | 1986-09-29 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara,Rt,Hu | Process for the production of heptakis/2,6-di-o-methyl-beta-cyclodextrin |
DE3400488A1 (en) | 1983-03-16 | 1984-09-20 | Kraftwerk Union AG, 4330 Mülheim | ELECTROHYDRAULIC COMPACT DRIVE FOR VALVES OF TURBO MACHINES, ESPECIALLY TURBINES |
EP0147685B1 (en) | 1983-12-17 | 1989-04-26 | Hoechst Aktiengesellschaft | Beta-cyclodextrin and process for its preparation |
EP0146841A3 (en) | 1983-12-17 | 1986-11-20 | Consortium für elektrochemische Industrie GmbH | Water soluble mixed ether of beta-cyclodextrin, and process for its preparation |
DE3346123A1 (en) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
MC1711A1 (en) | 1984-11-26 | 1986-09-22 | Ciba Geigy Ag | ALKYLIDENE-DIOXY COMPOUND |
MC1710A1 (en) * | 1984-11-26 | 1986-09-22 | Ciba Geigy Ag | NITROGEN COMPOUNDS OF OXO DERIVATIVES |
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
WO1994004145A1 (en) | 1992-08-21 | 1994-03-03 | Dana Farber Cancer Institute | Treatment of human viral infections |
AU3684395A (en) | 1994-10-06 | 1996-05-02 | Leon T. Atlas | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases |
US5763625A (en) * | 1995-04-25 | 1998-06-09 | Wisconsin Alumni Research Foundation | Synthesis and use of β-lapachone analogs |
US6245807B1 (en) * | 1995-08-24 | 2001-06-12 | Dana-Farber Cancer Institute | Treatment of human prostate disease |
WO1997008162A1 (en) * | 1995-08-24 | 1997-03-06 | Dana-Farber Cancer Institute | Beta-lapachone derivatives as antitumor agents |
AU6777596A (en) * | 1995-08-25 | 1997-03-19 | Dana-Farber Cancer Institute | Treatment of human prostate disease with beta-lapachone derivatives |
US5883270A (en) | 1996-02-20 | 1999-03-16 | Wisconsin Alumni Research Foundation | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth |
EP1261337B1 (en) | 2000-02-28 | 2008-09-10 | The University Of British Columbia | Topoisomerase inhibitors for treatment of surgical adhesions |
WO2003090710A1 (en) | 2002-04-23 | 2003-11-06 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
-
2001
- 2001-10-10 US US09/975,776 patent/US6962944B2/en not_active Expired - Fee Related
-
2002
- 2002-07-31 BR BR0211613-8A patent/BR0211613A/en not_active IP Right Cessation
- 2002-07-31 MX MXPA04000994A patent/MXPA04000994A/en active IP Right Grant
- 2002-07-31 AU AU2002313713A patent/AU2002313713B2/en not_active Ceased
- 2002-07-31 KR KR1020047001569A patent/KR100734341B1/en not_active IP Right Cessation
- 2002-07-31 CA CA002455567A patent/CA2455567A1/en not_active Abandoned
- 2002-07-31 EP EP02753423A patent/EP1420777A4/en not_active Withdrawn
- 2002-07-31 EA EA200400242A patent/EA007075B1/en not_active IP Right Cessation
- 2002-07-31 JP JP2003516456A patent/JP2005507861A/en active Pending
- 2002-07-31 NZ NZ531335A patent/NZ531335A/en unknown
- 2002-07-31 WO PCT/US2002/024262 patent/WO2003011224A2/en active Application Filing
- 2002-07-31 CN CNA028190297A patent/CN1561209A/en active Pending
- 2002-07-31 IL IL16010802A patent/IL160108A0/en unknown
-
2008
- 2008-07-21 IL IL192937A patent/IL192937A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969163A (en) * | 1996-02-20 | 1999-10-19 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth |
WO2000061142A1 (en) * | 1999-04-14 | 2000-10-19 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308180B2 (en) | 2005-08-31 | 2016-04-12 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
Also Published As
Publication number | Publication date |
---|---|
US6962944B2 (en) | 2005-11-08 |
US20030091639A1 (en) | 2003-05-15 |
KR100734341B1 (en) | 2007-07-03 |
CN1561209A (en) | 2005-01-05 |
EP1420777A4 (en) | 2009-03-04 |
IL192937A0 (en) | 2009-02-11 |
EA200400242A1 (en) | 2004-12-30 |
WO2003011224A2 (en) | 2003-02-13 |
EA007075B1 (en) | 2006-06-30 |
NZ531335A (en) | 2007-08-31 |
MXPA04000994A (en) | 2005-02-17 |
EP1420777A2 (en) | 2004-05-26 |
AU2002313713B2 (en) | 2007-03-29 |
IL160108A0 (en) | 2004-06-20 |
CA2455567A1 (en) | 2003-02-13 |
JP2005507861A (en) | 2005-03-24 |
BR0211613A (en) | 2004-11-09 |
KR20040054667A (en) | 2004-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003011224A3 (en) | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same | |
ES2620413T3 (en) | Topical anthelmintic veterinary formulations | |
PT831825E (en) | PHARMACEUTICAL FORMULATIONS OF CAMPTOTECIN DERIVATIVES HIGHLY LIPOFILOS | |
CA2543722A1 (en) | Tocopherol-modified therapeutic drug compounds | |
WO2004017940A3 (en) | Pharmaceutically active lipid based formulation of sn38 | |
WO2006014673A3 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
CA2304704A1 (en) | Formulations and methods for reducing toxicity of antineoplastic agents | |
WO2004105694A3 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
WO2003070236A3 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
BRPI0409427A (en) | compound, use thereof, pharmaceutical composition, method of treating a human suffering from a hyperproliferative disease, and process for the preparation of a compound or a pharmaceutically acceptable salt, ester or prodrug thereof | |
CA2282082A1 (en) | Microgranules containing cisplatin | |
JP7280870B2 (en) | Treatment of skin disorders | |
EP1458734A4 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer | |
CA2992376C (en) | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs | |
Zackheim | Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis | |
JP2003509372A (en) | Formulations for parenteral use of estramustine phosphate and amino acids | |
JP4361789B2 (en) | Treatment of hyperproliferative disorders of the body surface | |
HUP0301334A2 (en) | Combined compositions against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolited | |
WO2013149538A1 (en) | Pharmaceutical composition | |
RU2618462C2 (en) | Method and improved pharmaceutical composition for acceleration of pde-5 inhibitor transdermal delivery | |
AU2002320964A1 (en) | Treatment of hyperproliferative conditions of body surfaces | |
US11510859B2 (en) | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs | |
WO2014009793A1 (en) | Diclofenac solution for external use | |
JP2000256186A (en) | Composition for pharyngeal disease | |
WO2003030915A1 (en) | Use of solamargine for treating skin tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10343091 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 160108 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003516456 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2455567 Country of ref document: CA Ref document number: PA/a/2004/000994 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047001569 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 167/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 531335 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002313713 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002753423 Country of ref document: EP Ref document number: 200400242 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028190297 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002753423 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002313713 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 192937 Country of ref document: IL |